Whilst TCR therapy requires HLA-restricted specificity and clinical efficacy depends on TCR affinity and the expression of MHC-antigen complexes on the tumor cells, CAR recognition of tumor target cells is HLA-unrestricted. This evidence concerns the gene HLA-C and neoplasm.